Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

BACKGROUND: The effect of interleukin 17-inhibitors on anterior uveitis (AU) in spondyloarthritis (SpA) is poorly understood. This study aimed to compare the risk of AU during treatment with secukinumab versus tumour necrosis factor inhibitors (TNFi). METHODS: Patients with SpA starting secukinumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindström, Ulf, Bengtsson, Karin, Olofsson, Tor, Di Giuseppe, Daniela, Glintborg, Bente, Forsblad-d'Elia, Helena, Jacobsson, Lennart T H, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522450/
https://www.ncbi.nlm.nih.gov/pubmed/34130984
http://dx.doi.org/10.1136/annrheumdis-2021-220420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522450/
https://www.ncbi.nlm.nih.gov/pubmed/34130984
http://dx.doi.org/10.1136/annrheumdis-2021-220420

Ejemplares similares